EUCTR2020-004986-38-PT进行中（未招募）1 期
A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis - NATIV3
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Able to understand the nature of the study, willing and able to comply with the study procedures and restrictions, and able to provide signed, dated and written informed consent obtained before any study-related activities, sampling and analysis.
- •2. The patient will be willing to continue on the study in case of moving or relocation during the first 72 weeks of the study.
- •3. Male or female, aged =18 years at the time of signing informed consent
- •4.If biopsy is performed before Screening, i.e. if a historical biopsy is available, a histological diagnosis of NASH with liver fibrosis must be made no more than 7 months before randomisation
- •5. Main cohort: Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):
- •a.Steatosis score =1
- •b.Activity score: A3 or A4
- •c.Fibrosis score: F2 or F3
- •Exploratory cohort: Patients who, upon central biopsy reading process, do not meet the eligibility criteria described above but fulfil the following criteria: diagnosis of NASH according to the Steatosis-ActivityFibrosis (SAF):
- •a) Steatosis score =1
- •b) Activity score =2 with SAF-Inflammation score =1 and SAF-Ballooning score =1
- •c) Fibrosis score: any stage (F1 to F4)
- •6. Model for End-Stage Liver Disease (MELD) score =12 (unless patient is on anticoagulants)
- •7. For patients receiving the concomitant medications listed below: no qualitative change in dose are allowed (changes having minimal clinical impact like temporary cessation/change between class of drugs are allowed), for the specified period prior to the historical liver biopsy or before Screening visit (whichever is longer) until Baseline visit (Visit 0):
- •a. Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
- •b. Vitamin E (if at a dose =400 IU/day): for at least 6 months
- •c. Statins for at least 3 months
- •8. For patients receiving concomitant medications not covered by criterion #7 (including but not limited to antidiabetic treatments other than GLP1 receptor agonists and SGLT2 inhibitors, antihypertensives, antidepressants, cardiovascular, antihyperlipidemic, etc) no qualitative change in dose are allowed for at least 3 months prior to Screening visit until Baseline visit (Visit 0)
- •9. For overweight/obese patient, history of at least 1 unsuccessful attempt to reduce body weight by diet and/or exercise within the past 6 years
- •10. Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
- •11. Criterion removed from Version 3.0 on
- •12. Patient agrees to follow recommendations with lifestyle modifications, which will be monitored throughout the whole study period.
- •13. Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation. Highly effective contraceptive methods are defined as follows: combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing sys
排除标准
- •Liver-related:
- •1. Documented causes of chronic liver disease other than NASH including, but not restricted to:
- •a. Viral hepatitis
- •b. Drug-induced liver disease
- •c. Alcoholic liver disease
- •d. Autoimmune hepatitis
- •e.Wilson's disease
- •f.Haemochromatosis
- •g.Primary biliary cholangitis
- •h.Primary sclerosing cholangitis
- •i.Alpha-1-antitrypsin deficiency
- •j. Chronic portal vein thrombosis or splenic vein thrombosis
- •2. Histologically documented liver cirrhosis in a historical biopsy (fibrosis stage F4) or suspicion at screening of cirrhosis based on clinic biochemical and imaging criteria
- •3. History or current diagnosis of hepatocellular carcinoma (HCC)
- •4. History of or planned liver transplant
- •5. Inability or unwillingness to undergo a liver biopsy at Screening (if a suitable historical biopsy is unavailable for central review) and at Week 72
- •6. Positive human immunodeficiency virus (HIV) serology
- •7. ALT or AST >5 × ULN
- •7.1. AST < 0.60 × ULN if the screening liver biopsy has to be performed in the scope of the study
- •7.2. Liver Stiffness Measurement (LSM) < 6 kPa by transient elastography (or equivalent) during screening if the screening liver biopsy has to be performed in the scope of the study.
- •8. Abnormal synthetic liver function as defined by Screening central laboratory evaluation of any of the following:
- •a. Albumin below the lower limit of the normal range
- •b. International normalised ratio (INR) =1.3 (unless patient is on anticoagulants)
- •c. Total bilirubin level =1.5 mg/dL (25.6 µmol/L) Patients with a history of Gilbert's syndrome can be enrolled if the direct bilirubin is =0.45 mg/dL (7.7 µmol/L)
- •9. Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males
- •10. Leucocytes count < LLN. A lower count is acceptable in patients with benign ethnic neutropenia, if considered to be clinical insignificant by the investigator.
- •11. Platelet count <140,000/µL.
- •12. Alkaline phosphatase (ALP) >2 × ULN
- •13. Patient currently receiving any approved treatment for NASH or obesity
- •14. Current or recent history (<5 years) of significant alcohol consumption, which is typically defined as higher than 30 g pure alcohol per day for men and as higher than 20 g pure alcohol per day for women
- •15. Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy
- •Glycaemia related:
- •16. HbA1c >9% at Screening
- •17. Diabetes mellitus other than type 2
- •18. Current treatment with insulin
- •19.Treatment with PPAR-gamma agonists 12 months before screening or historical biopsy, or any history of stopping TZD due to safety reason
- •Obesity related:
- •20. Bariatric surgery: Restrictive procedures (e.g. lap banding, intragastric balloon, sleeve gastrectomy) are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures (e.g. biliopancreatic diversion) and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy. Liposuction and/or abdominoplasty are allowed if performed >6 months before qualifying liver biopsy. Planned bariatric surgery is not allowed
- •21. Participation in an organised weight-loss programme within 3 months of the study, or planned participation through Week 72
- •Cardiovascular related:
- •22. History of heart failure with reduced left ventricular ejection fraction (LVEF) defined as any past measurement of LVEF = 40%
- •23. N-terminal-prohormone B-type natriuretic
研究者
相似试验
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, administered as allergen based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis (with or without asthma)Grass pollen allergic rhinoconjunctivitisMedDRA version: 9.1Level: LLTClassification code 10039085Term: Rhinitis allergicMedDRA version: 9.1Level: PTClassification code 10039085Term: Rhinitis allergicEUCTR2008-003906-32-CZStallergenes S.A.336
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy - A Phase II dose-finding study of atacicept in RAMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-004140-23-PTMerck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany240
进行中（未招募）
1 期
A clinical study to assess the long-term efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosison-alcoholic Steatohepatitis (NASH)MedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-004986-38-HUInventiva S.A.1,200
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, multicentre trial to access the safety and efficacy of pre-treatment with DF01 during late pregnancy in reducing prolonged labour.Pre-treatment during late pregnancy to reduce prolonged labour.EUCTR2006-005839-20-SEDilafor AB
进行中（未招募）
不适用
A single-dose study to investigate the effects of 3 different doses of inhaled AZD2115 in COPD patientsAZD2115 is being developed to treat chronic obstructive pulmonary disease (COPD).MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-004641-41-PLAstraZeneca AB36